ASN 004

Drug Profile

ASN 004

Alternative Names: MUC-1 cancer vaccine - Ascend Biopharmaceuticals

Latest Information Update: 10 Oct 2015

Price : $50

At a glance

  • Originator Ascend Biopharmaceuticals
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Solid tumours

Most Recent Events

  • 09 Oct 2015 Preclinical trials in Breast cancer and other Solid tumours in Australia (Parenteral)
  • 09 Oct 2015 Ascend Biopharmaceuticals plans a phase Ib trial for Breast cancer (Early-stage disease) in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top